Amplify Weight Loss Drug & Treatment ETF (THNR)
NYSEARCA: THNR · Real-Time Price · USD
21.66
-0.06 (-0.28%)
At close: May 13, 2025, 4:00 PM
21.66
0.00 (0.00%)
After-hours: May 13, 2025, 8:00 PM EDT
-0.28% (1D)
| Assets | $2.80M |
| Expense Ratio | 0.59% |
| PE Ratio | 25.21 |
| Shares Out | 130,000 |
| Dividend (ttm) | $0.22 |
| Dividend Yield | 1.01% |
| Ex-Dividend Date | Dec 30, 2024 |
| Payout Ratio | 25.97% |
| 1-Year Return | n/a |
| Volume | 1,546 |
| Open | 21.58 |
| Previous Close | 21.72 |
| Day's Range | 21.58 - 21.66 |
| 52-Week Low | 18.56 |
| 52-Week High | 28.19 |
| Beta | n/a |
| Holdings | 28 |
| Inception Date | May 21, 2024 |
About THNR
Fund Home PageThe Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Asset Class Equity
Category Health
Region Global
Stock Exchange NYSEARCA
Ticker Symbol THNR
ETF Provider Amplify Investments
Index Tracked VettaFi Weight Loss Drug Index
Top 10 Holdings
69.95% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 14.17% |
| Novo Nordisk A/S | NVO | 13.39% |
| Hims & Hers Health, Inc. | HIMS | 6.58% |
| Chugai Pharmaceutical Co., Ltd. | 4519 | 6.32% |
| Innovent Biologics, Inc. | 1801 | 5.58% |
| Teva Pharmaceutical Industries Limited | TEVA | 5.30% |
| West Pharmaceutical Services, Inc. | WST | 4.91% |
| Roche Holding AG | ROG | 4.67% |
| AstraZeneca PLC | AZN | 4.56% |
| Pfizer Inc. | PFE | 4.48% |
News
SILJ, HACK, THNR: Trends in Thematic Investing
Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.
10 months ago - Schwab Network
Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.
Other symbols: OZEM
11 months ago - Investopedia